Intracranial biomarkers for anterior thalamic deep brain stimulation in epilepsy: a long-term observational study
Brain · 04.11.2026 · 149 (11) · 3806-3820
DOI: 10.1093/brain/awag120 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Brain, online erschienen am 03.04.2026. Verfasst von Giovanna Aiello und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Science and Technology, ETH Zurich, Zurich 8092, Switzerland. Hauptthemen laut MEDLINE: Deep Brain Stimulation, Anterior Thalamic Nuclei, Drug Resistant Epilepsy, Epilepsy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss National Science Foundation.
Abstract (Originalsprache)
Deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) is an established treatment for patients with drug-refractory epilepsy, yet long-term therapeutic outcomes are highly variable and challenging to predict. This variability is compounded by the delayed and gradual effects of DBS, the difficulty of consistent seizure monitoring, and the absence of physiological biomarkers to inform treatment. In this study, we analysed longitudinal intracranial recordings over an observational period of 4 years from a cohort of 22 patients with ANT DBS. Our primary goal is the identification of neurophysiological signatures that could predict and track clinical DBS response. Our results show that DBS responders and non-responders exhibit distinct ANT spectral trajectories over time, with responders showing a progressive increase in higher frequencies (β1 and γ) and decreased lower-frequency (δ and θ) activity in comparison to non-responders. Notably, these dynamic biomarkers, particularly high- to low-frequency ratios (e.g. β1/θ), enabled the early discrimination of clinical outcomes. Additionally, we provide evidence of robust circadian and multidien rhythms in ANT local field potentials, with further analyses supporting the feasibility of adaptive stimulation protocols to improve therapeutic outcomes. Together, these findings propose ANT spectral dynamics in outpatient settings as a promising tool for early prediction of therapeutic efficacy and pave the way for biomarker-guided optimization of DBS therapy in epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Science and Technology, ETH Zurich, Zurich 8092, Switzerland.
- Department of Epileptology, Swiss Epilepsy Center Klinik Lengg, Zurich 8008, Switzerland.
- Department of Neurosurgery, University Hospital Zurich, Zurich 8091, Switzerland.
- Institute for Neuroscience, ETH Zurich, Zurich 8057, Switzerland.
ORCID-Profile: Giovanna Aiello
Förderung
- Swiss National Science Foundation
Zitieren
APA
Aiello, G., Elshahabi, A., Stieglitz, L., Belvedere, A., Dubcek, T., Polania, R., & Imbach, L. (2026). Intracranial biomarkers for anterior thalamic deep brain stimulation in epilepsy: a long-term observational study. Brain, 149(11), 3806-3820. https://doi.org/10.1093/brain/awag120
Vancouver
Aiello G, Elshahabi A, Stieglitz L, Belvedere A, Dubcek T, Polania R, et al. Intracranial biomarkers for anterior thalamic deep brain stimulation in epilepsy: a long-term observational study. Brain. 2026;149(11):3806-3820. doi:10.1093/brain/awag120
BibTeX
@article{Aiello2026,
author = {Aiello, Giovanna and Elshahabi, Adham and Stieglitz, Lennart and Belvedere, Anina and Dubcek, Tena and Polania, Rafael and Imbach, Lukas},
title = {Intracranial biomarkers for anterior thalamic deep brain stimulation in epilepsy: a long-term observational study},
journal = {Brain},
year = {2026},
volume = {149},
number = {11},
pages = {3806--3820},
doi = {10.1093/brain/awag120}
}
EUVIMED